I am a biologist and drug development scientist with a background in immunology and over a decade of experience supporting pharmaceutical and biotechnology programs across discovery, translational, and early clinical development. My work sits at the interface of biology and quantitative modeling, with a strong focus on applying model-informed drug development (MIDD) principles to real-world decision making.
I specialize in biologics and oncology drug development, including antibody-drug conjugates (ADCs), T-cell engagers (TCEs), monoclonal antibodies, bispecific antibodies, and cell-based therapies. I contribute biological insight to quantitative systems pharmacology (QSP) and PK/PD modeling efforts by shaping mechanistic model structures, defining biologically realistic assumptions, and identifying fit-for-purpose preclinical and clinical data for calibration and validation.
My primary interests include translational strategy, first-in-human dose selection, exposure-response analysis, treatment scheduling, and safety-efficacy trade-offs across therapeutic modalities. I regularly work with heterogeneous data sources, both preclinical and clinical, to inform dose justification and development strategy.
In addition to project delivery, I am actively involved in scientific communication, internal training, and cross-functional collaboration, helping bridge gaps between biology, clinical pharmacology, dose selection.
I am a biologist and drug development scientist with a background in immunology and over a decade of experience supporting pharmaceutical and biotechnology programs across discovery, translational, and early clinical development. My work sits at the interface of biology and quantitative modeling, with a strong focus on applying model-informed drug development (MIDD) principles to real-world decision making.
I specialize in biologics and oncology drug development, including antibody-drug conjugates (ADCs), T-cell engagers (TCEs), monoclonal antibodies, bispecific antibodies, and cell-based therapies. I contribute biological insight to quantitative systems pharmacology (QSP) and PK/PD modeling efforts by shaping mechanistic model structures, defining biologically realistic assumptions, and identifying fit-for-purpose preclinical and clinical data for calibration and validation.
My primary interests include translational strategy, first-in-human dose selection, exposure-response analysis, treatment scheduling, and safety-efficacy trade-offs across therapeutic modalities. I regularly work with heterogeneous data sources, both preclinical and clinical, to inform dose justification and development strategy.
In addition to project delivery, I am actively involved in scientific communication, internal training, and cross-functional collaboration, helping bridge gaps between biology, clinical pharmacology, dose selection.